# Evolv Technologies

Type: Company (EVLV)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/evolv-technologies
Canonical HTML page: https://getbiobrief.com/entity/evolv-technologies

## Recent coverage (1 stories)

### Skye Bioscience Q4 Preview: Obesity Pipeline and Nimacimab Catalysts in Focus
2026-03-09 22:00:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Skye Bioscience is set to report Q4 2025 results as the market eyes progress on its Phase 2 nimacimab trial for obesity. The company's pivot toward the metabolic space positions it as a key player in the next-gen CB1 inhibitor race.
Full story: https://getbiobrief.com/story/skye-bioscience-q4-2025-earnings-preview-obesity-market

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.